{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:27:18Z","timestamp":1714004838183},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,24]]},"DOI":"10.7759\/cureus.58886","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T08:15:25Z","timestamp":1713946525000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Saudi Patients With Atrial Fibrillation"],"prefix":"10.7759","author":[{"given":"Mosaad","family":"Almegren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1747493019897870","article-title":"Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge","volume":"16","author":"Lippi G","year":"2021","unstructured":"Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021, 16:217-21. 10.1177\/1747493019897870","journal-title":"Int J Stroke"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.3702","article-title":"Temporal association between episodes of atrial fibrillation and risk of ischemic stroke","volume":"6","author":"Singer DE","year":"2021","unstructured":"Singer DE, Ziegler PD, Koehler JL, Sarkar S, Passman RS. Temporal association between episodes of atrial fibrillation and risk of ischemic stroke. JAMA Cardiol. 2021, 6:1364-9. 10.1001\/jamacardio.2021.3702","journal-title":"JAMA Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.121.036757","article-title":"Effectiveness and safety of anticoagulation therapy in frail patients with atrial fibrillation","volume":"53","author":"Kim D","year":"2022","unstructured":"Kim D, Yang PS, Sung JH, et al.. Effectiveness and safety of anticoagulation therapy in frail patients with atrial fibrillation. Stroke. 2022, 53:1873-82. 10.1161\/STROKEAHA.121.036757","journal-title":"Stroke"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.0199","article-title":"Outcomes in a warfarin-treated population with atrial fibrillation","volume":"1","author":"Bj\u00f6rck F","year":"2016","unstructured":"Bj\u00f6rck F, Renlund H, Lip GY, Wester P, Svensson PJ, Sj\u00e4lander A. Outcomes in a warfarin-treated population with atrial fibrillation. JAMA Cardiol. 2016, 1:172-80. 10.1001\/jamacardio.2016.0199","journal-title":"JAMA Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.002329","article-title":"Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study","volume":"44","author":"Bj\u00f6rck S","year":"2013","unstructured":"Bj\u00f6rck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013, 44:3103-8. 10.1161\/STROKEAHA.113.002329","journal-title":"Stroke"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2174\/157489010791515269","article-title":"Old versus new anticoagulants: focus on pharmacology","volume":"5","author":"Benmira S","year":"2010","unstructured":"Benmira S, Banda ZK, Bhattacharya V. Old versus new anticoagulants: focus on pharmacology. Recent Pat Cardiovasc Drug Discov. 2010, 5:120-37. 10.2174\/157489010791515269","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al.. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011, 365:883-91. 10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger CB","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al.. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011, 365:981-92. 10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly SJ","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al.. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361:1139-51. 10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano RP","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al.. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013, 369:2093-104. 10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s43044-022-00259-9","article-title":"Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!","volume":"74","author":"Abdelnabi M","year":"2022","unstructured":"Abdelnabi M, Benjanuwattra J, Okasha O, Almaghraby A, Saleh Y, Gerges F. Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!. Egypt Heart J. 2022, 74:18. 10.1186\/s43044-022-00259-9","journal-title":"Egypt Heart J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234048","article-title":"Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN study","volume":"15","author":"Hendriks T","year":"2020","unstructured":"Hendriks T, McGregor S, Rakesh S, Robinson J, Ho KM, Baker R. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN study. PLoS One. 2020, 15:10.1371\/journal.pone.0234048","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft DW","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976, 16:31-41. 10.1159\/000180580","journal-title":"Nephron"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage BF","year":"2001","unstructured":"Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001, 285:2864-70. 10.1001\/jama.285.22.2864","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters R","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010, 138:1093-100. 10.1378\/chest.10-0134","journal-title":"Chest"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman S","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005, 3:692-4. 10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026666","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation and valve replacement or repair","volume":"11","author":"Mentias A","year":"2022","unstructured":"Mentias A, Saad M, Michael M, et al.. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation and valve replacement or repair. J Am Heart Assoc. 2022, 11:e026666. 10.1161\/JAHA.122.026666","journal-title":"J Am Heart Assoc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1668521","article-title":"All-cause mortality risk with direct oral anticoagulants and warfarin in the primary treatment of venous thromboembolism","volume":"118","author":"Roetker NS","year":"2018","unstructured":"Roetker NS, Lutsey PL, Zakai NA, Alonso A, Adam TJ, MacLehose RF. All-cause mortality risk with direct oral anticoagulants and warfarin in the primary treatment of venous thromboembolism. Thromb Haemost. 2018, 118:1637-45. 10.1055\/s-0038-1668521","journal-title":"Thromb Haemost"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265998","article-title":"Long term follow up of direct oral anticoagulants and warfarin therapy on stroke, with all-cause mortality as a competing risk, in people with atrial fibrillation: sentinel network database study","volume":"17","author":"de Lusignan S","year":"2022","unstructured":"de Lusignan S, Hobbs FD, Liyanage H, et al.. Long term follow up of direct oral anticoagulants and warfarin therapy on stroke, with all-cause mortality as a competing risk, in people with atrial fibrillation: sentinel network database study. PLoS One. 2022, 17:10.1371\/journal.pone.0265998","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2505","article-title":"Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care","volume":"362","author":"Vinogradova Y","year":"2018","unstructured":"Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018, 362:k2505. 10.1136\/bmj.k2505","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005008","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)","volume":"130","author":"Halperin JL","year":"2014","unstructured":"Halperin JL, Hankey GJ, Wojdyla DM, et al.. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014, 130:138-46. 10.1161\/CIRCULATIONAHA.113.005008","journal-title":"Circulation"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-019-1116-1","article-title":"Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment na\u00efve non-valvular atrial fibrillation patients in the US Department of defense population","volume":"19","author":"Gupta K","year":"2019","unstructured":"Gupta K, Trocio J, Keshishian A, et al.. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment na\u00efve non-valvular atrial fibrillation patients in the US Department of defense population. BMC Cardiovasc Disord. 2019, 19:142. 10.1186\/s12872-019-1116-1","journal-title":"BMC Cardiovasc Disord"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.022636","article-title":"Higher incidence of ischemic stroke in patients taking novel oral anticoagulants","volume":"49","author":"Shpak M","year":"2018","unstructured":"Shpak M, Ramakrishnan A, Nadasdy Z, Cowperthwaite M, Fanale C. Higher incidence of ischemic stroke in patients taking novel oral anticoagulants. Stroke. 2018, 49:2851-6. 10.1161\/STROKEAHA.118.022636","journal-title":"Stroke"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1714918","article-title":"Bleeding risk in non-valvular atrial fibrillation patients receiving direct oral anticoagulants and warfarin: a systematic review and meta-analysis of observational studies","volume":"4","author":"Wang YP","year":"2020","unstructured":"Wang YP, Kehar R, Iansavitchene A, Lazo-Langner A. Bleeding risk in non-valvular atrial fibrillation patients receiving direct oral anticoagulants and warfarin: a systematic review and meta-analysis of observational studies. TH Open. 2020, 4:e145-52. 10.1055\/s-0040-1714918","journal-title":"TH Open"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.007230","article-title":"Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation","volume":"14","author":"Jackevicius CA","year":"2021","unstructured":"Jackevicius CA, Lu L, Ghaznavi Z, Warner AL. Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2021, 14:e007230. 10.1161\/CIRCOUTCOMES.120.007230","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2022-002043","article-title":"Oral anticoagulants, time in therapeutic range and renal function over time in real-life patients with atrial fibrillation and chronic kidney disease","volume":"9","author":"Batra G","year":"2022","unstructured":"Batra G, Modica A, Renlund H, Larsson A, Christersson C, Held C. Oral anticoagulants, time in therapeutic range and renal function over time in real-life patients with atrial fibrillation and chronic kidney disease. Open Heart. 2022, 9:10.1136\/openhrt-2022-002043","journal-title":"Open Heart"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease","volume":"141","author":"Stanifer JW","year":"2020","unstructured":"Stanifer JW, Pokorney SD, Chertow GM, et al.. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020, 141:1384-92. 10.1161\/CIRCULATIONAHA.119.044059","journal-title":"Circulation"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011373.pub2","article-title":"Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease","volume":"11","author":"Kimachi M","year":"2017","unstructured":"Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev. 2017, 11:CD011373. 10.1002\/14651858.CD011373.pub2","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/247350-efficacy-and-safety-of-direct-oral-anticoagulants-versus-warfarin-in-saudi-patients-with-atrial-fibrillation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T08:15:30Z","timestamp":1713946530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/247350-efficacy-and-safety-of-direct-oral-anticoagulants-versus-warfarin-in-saudi-patients-with-atrial-fibrillation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.58886","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,24]]}}}